Fredun Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Fredun Pharmaceuticals has been growing earnings at an average annual rate of 46.1%, while the Pharmaceuticals industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 28.5% per year. Fredun Pharmaceuticals's return on equity is 13.5%, and it has net margins of 4.5%.
Key information
46.1%
Earnings growth rate
42.7%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 28.5% |
Return on equity | 13.5% |
Net Margin | 4.5% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Fredun Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 3,903 | 177 | 355 | 0 |
30 Jun 24 | 3,649 | 174 | 356 | 0 |
31 Mar 24 | 3,482 | 156 | 345 | 0 |
31 Dec 23 | 4,425 | 183 | 453 | 0 |
30 Sep 23 | 3,004 | 130 | 282 | 0 |
30 Jun 23 | 2,874 | 123 | 118 | 0 |
31 Mar 23 | 2,747 | 108 | 278 | 0 |
31 Dec 22 | 1,498 | 58 | 210 | -1 |
30 Sep 22 | 2,423 | 83 | 260 | 0 |
30 Jun 22 | 2,250 | 70 | 109 | 1 |
31 Mar 22 | 2,245 | 63 | 256 | 0 |
31 Dec 21 | 1,957 | 39 | 187 | 1 |
30 Sep 21 | 1,877 | 33 | 182 | 0 |
30 Jun 21 | 1,655 | 23 | 182 | 0 |
31 Mar 21 | 1,338 | 20 | 177 | 0 |
31 Dec 20 | 1,155 | 20 | 190 | -1 |
30 Sep 20 | 966 | 17 | 187 | 0 |
30 Jun 20 | 963 | 17 | 182 | 0 |
31 Mar 20 | 1,127 | 19 | 174 | 0 |
31 Dec 19 | 1,177 | 32 | 218 | 1 |
30 Sep 19 | 1,177 | 39 | 215 | 0 |
30 Jun 19 | 1,074 | 53 | 220 | 0 |
31 Mar 19 | 961 | 45 | 227 | 0 |
31 Dec 18 | 845 | 41 | 90 | 0 |
30 Sep 18 | 720 | 26 | 82 | 0 |
30 Jun 18 | 652 | 8 | 81 | 0 |
31 Mar 18 | 584 | 18 | 120 | 0 |
31 Dec 17 | 552 | 14 | 61 | 0 |
30 Sep 17 | 541 | 13 | 67 | 0 |
30 Jun 17 | 493 | 12 | 49 | 0 |
31 Mar 17 | 567 | 14 | 62 | 0 |
31 Dec 16 | 552 | 15 | 57 | 0 |
30 Sep 16 | 552 | 16 | 51 | 0 |
30 Jun 16 | 509 | 13 | 39 | 0 |
31 Mar 16 | 423 | 11 | 48 | 0 |
31 Dec 15 | 338 | 4 | 40 | 0 |
30 Sep 15 | 269 | 4 | 38 | 0 |
30 Jun 15 | 278 | 4 | 38 | 0 |
31 Mar 15 | 253 | 3 | 37 | 0 |
31 Dec 14 | 240 | 6 | 35 | 0 |
30 Sep 14 | 238 | 4 | 35 | 0 |
30 Jun 14 | 228 | 4 | 34 | 0 |
31 Mar 14 | 213 | 2 | 32 | 0 |
31 Dec 13 | 178 | 1 | 27 | 0 |
Quality Earnings: 539730 has a high level of non-cash earnings.
Growing Profit Margin: 539730's current net profit margins (4.5%) are higher than last year (4.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 539730's earnings have grown significantly by 46.1% per year over the past 5 years.
Accelerating Growth: 539730's earnings growth over the past year (35.6%) is below its 5-year average (46.1% per year).
Earnings vs Industry: 539730 earnings growth over the past year (35.6%) exceeded the Pharmaceuticals industry 19.1%.
Return on Equity
High ROE: 539730's Return on Equity (13.5%) is considered low.